Synovio Therapeutics

About

Funding history · 1 round · — total

Q&A

What is Synovio Therapeutics' primary focus?

Synovio Therapeutics is focused on developing a novel small molecule, Fenchone 1D, as a drug candidate for Osteoarthritis therapy.

When was Synovio Therapeutics founded?

Synovio Therapeutics was founded in January 2025.

How many employees does Synovio Therapeutics currently have?

Synovio Therapeutics has 1-10 employees.

What is Synovio Therapeutics' current funding stage?

Synovio Therapeutics is currently in the Pre-Seed funding stage.

Which investor participated in Synovio Therapeutics' funding round in September 2025?

The Israel Innovation Authority participated in Synovio Therapeutics' funding round in September 2025.

What sector does Synovio Therapeutics operate in?

Synovio Therapeutics operates in the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.

What is the product stage of Synovio Therapeutics' offering?

Synovio Therapeutics' product is currently in the R&D stage.

Team · 1

adi Sagiv Meister

Founder · Founder

Sectors & technology